title: Infective and inactivated filamentous phage as carriers for immunogenic peptides.
abstract: The focus of this study is on development of vaccines using filamentous phage as a delivery vector for immunogenic peptides. The use of phage as a carrier for immunogenic peptides provides significant benefits such as high immunogenicity, low production costs, and high stability of phage preparations. However, introduction of live recombinant phage into the environment might represent a potential ecological problem. This, for example, may occur when vaccines are used in oral or nasal formulations in field conditions for wild and feral animals. To address this issue, comparative studies of antigenic properties of live and inactivated (non-viable) phage were accomplished. Inactivated phage, if released, will not propagate and will degrade as any other protein. In these experiments, a model phage clone that was previously selected from a phage display library and shown to stimulate production of anti-sperm antibodies with contraceptive properties was used. Multiple methods of phage inactivation were tested, including drying, freezing, autoclaving, heating, and UV irradiation. Under studied conditions, heating at 76°C for 3h, UV irradiation, and autoclaving resulted in complete phage inactivation. Phage samples treated by heat and UV were characterized by spectrophotometry and electron microscopy. To test antigenicity, live and inactivated phage preparations were injected into mice and antibody responses assayed by ELISA. It was found that phage killed by heat causes little to no immune responses, probably due to destruction of phage particles. In contrast, UV-inactivated phage stimulated production of IgG serum antibodies at the levels comparable to live phage. Thus, vaccines formulated to include UV-inactivated filamentous phage might represent environmentally safe alternatives to live phage vaccines.
authors.affiliation: Scott-Ritchey Research Center, College of Veterinary Medicine, Auburn University, Auburn, AL 36849, USA. samoiti@auburn.edu
authors.forename: Tatiana I
authors.initials: TI
authors.lastname: Samoylova
authors.forename: Mandy D
authors.initials: MD
authors.lastname: Norris
authors.forename: Alexandre M
authors.initials: AM
authors.lastname: Samoylov
authors.forename: Anna M
authors.initials: AM
authors.lastname: Cochran
authors.forename: Karen G
authors.initials: KG
authors.lastname: Wolfe
authors.forename: Valery A
authors.initials: VA
authors.lastname: Petrenko
authors.forename: Nancy R
authors.initials: NR
authors.lastname: Cox
mesh_terms: D000818:Animals; D000906:Antibodies / Q000097:blood; D003890:Desiccation; D004203:Disinfection / Q000379:methods; D004337:Drug Carriers; D004797:Enzyme-Linked Immunosorbent Assay; D005615:Freezing; D005822:Genetic Vectors; D006358:Hot Temperature; D017912:Inovirus / Q000235:genetics* / Q000276:immunology* / Q000528:radiation effects; D008297:Male; D051379:Mice; D013094:Spermatozoa / Q000276:immunology; D014466:Ultraviolet Rays; D022642:Vaccines, Contraceptive / Q000008:administration & dosage / Q000276:immunology*; D015164:Vaccines, Inactivated / Q000008:administration & dosage / Q000276:immunology; D014614:Vaccines, Synthetic / Q000008:administration & dosage / Q000276:immunology; D038301:Virus Inactivation / Q000528:radiation effects
chemical_list: D000906:Antibodies; D004337:Drug Carriers; D022642:Vaccines, Contraceptive; D015164:Vaccines, Inactivated; D014614:Vaccines, Synthetic